3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Brain Neoplasms
8
Breast Neoplasms
5
Neoplasms
4
Head and Neck Neoplasms
3
Central Nervous System Neoplasms
3
Uterine Cervical Neoplasms
2
Unspecified Adult Solid Tumor, Protocol Specific
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Oligodendroglioma
2
Melanoma
2
Lung Neoplasms
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Carcinoma, Non-Small-Cell Lung
2
Astrocytoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Interventions
Surveys and Questionnaires
6
Methods
6
Radiotherapy
5
Cisplatin
5
pembrolizumab
4
durvalumab
3
Sentinel Lymph Node Biopsy
3
Radiosurgery
3
Palliative Care
3
Indocyanine Green
3
Early Intervention, Educational
3
Brachytherapy
3
Bleomycin
3
tremelimumab
2
aldesleukin
2
Surgical Procedures, Operative
2
Radiation
2
Paclitaxel
2
Interviews as Topic
2
Immunoglobulin G
2
Imiquimod
2
Gemcitabine
2
Electrochemotherapy
2
Drug Therapy
2
Disulfides
2
Dehydroepiandrosterone
2
Counseling
2
Carboplatin
2
Biopsy
2
Bevacizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Vulvar Neoplasms
×
alovudine
×
Clear all
NCT01399658
2023-03-14
AMIGO
Dana-Farber Cancer Institute
Phase 2
Completed
93 enrolled
5 charts